Table 2 Bleeding events
Total | ||||
|---|---|---|---|---|
| Â | Any bleeding | Major bleeding | ||
Without concomitant unfractionated heparin (n = 229) | 13 | (5.68%) | 5 | (5.68%) |
With concomitant unfractionated heparin (n = 47) | 6 | (12.77%) | 4 | (8.51%) |
Total (n = 276) | 19 | (6.88%) | 9 | (3.26%) |
AT1500 group | Â | Â | ||
| Â | Any bleeding | Major bleeding | ||
Without concomitant unfractionated heparin (n = 170) | 6 | (3.53%) | 3 | (1.76%) |
With concomitant unfractionated heparin (n = 60) | 10 | (16.67%) | 4 | (6.67%) |
Total (n = 230) | 16 | (6.96%) | 7 | (3.04%) |
AT3000 group | Â | Â | ||
| Â | Any bleeding | Major bleeding | ||
Without concomitant unfractionated heparin (n = 38) | 3 | (7.89%) | 2 | (5.26%) |
With concomitant unfractionated heparin (n = 8) | 0 | (0.0%) | 0 | (0.0%) |
Total (n = 46) | 3 | (6.52%) | 2 | (4.35%) |